RadNet (RDNT) Projected to Post Earnings on Sunday

RadNet logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • RadNet is expected to report Q3 2026 results before the market opens on November 8, with analysts forecasting earnings of $0.2214 per share and revenue of $639.97 million. The earnings call is scheduled for November 9 at 10:30 a.m. ET.
  • In its prior quarter, RadNet exceeded expectations with EPS of $0.29 versus the $0.20 consensus and revenue of $622.72 million, up 25% year over year.
  • Analyst sentiment remains broadly positive, with a consensus “Buy” rating and an average price target of $90, compared with the stock’s recent price of $73.49.
  • Interested in RadNet? Here are five stocks we like better.

RadNet (NASDAQ:RDNT - Get Free Report) is anticipated to release its Q3 2026 results before the market opens on Sunday, November 8th. Analysts expect RadNet to announce earnings of $0.2214 per share and revenue of $639.97 million for the quarter. Interested persons can check the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Monday, November 9, 2026 at 10:30 AM ET.

RadNet (NASDAQ:RDNT - Get Free Report) last released its earnings results on Monday, August 10th. The medical research company reported $0.29 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.20 by $0.09. RadNet had a positive return on equity of 2.61% and a negative net margin of 0.93%. The business had revenue of $622.72 million for the quarter, compared to analyst estimates of $610.87 million. During the same quarter in the previous year, the company posted $0.31 earnings per share. The company's revenue for the quarter was up 25.0% compared to the same quarter last year. On average, analysts expect RadNet to post $0.49 EPS for the current fiscal year and $0.87 EPS for the next fiscal year.

RadNet Price Performance

RadNet stock opened at $73.49 on Friday. RadNet has a 12 month low of $50.82 and a 12 month high of $85.84. The company has a debt-to-equity ratio of 0.94, a current ratio of 1.48 and a quick ratio of 1.48. The business has a 50 day simple moving average of $72.56 and a 200-day simple moving average of $65.30. The stock has a market capitalization of $5.78 billion, a PE ratio of -272.18 and a beta of 1.41.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on RDNT. Jefferies Financial Group reiterated a "buy" rating on shares of RadNet in a research report on Friday, July 31st. Weiss Ratings restated a "sell (d-)" rating on shares of RadNet in a research report on Friday, August 7th. Zacks Research upgraded shares of RadNet from a "hold" rating to a "strong-buy" rating in a research note on Friday, October 9th. Barclays lifted their target price on shares of RadNet from $65.00 to $79.00 and gave the company an "overweight" rating in a report on Friday, August 28th. Finally, Raymond James Financial reaffirmed a "strong-buy" rating on shares of RadNet in a report on Tuesday, September 22nd. Three equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, RadNet has a consensus rating of "Buy" and an average target price of $90.00.

Read Our Latest Stock Analysis on RDNT

RadNet Company Profile

(Get Free Report)

RadNet, Inc NASDAQ: RDNT is an outpatient diagnostic imaging company that operates imaging centers and provides related healthcare services. Its facilities offer diagnostic radiology and imaging procedures used to help detect, diagnose, and monitor medical conditions.

The company's services generally include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound, X-ray, and other imaging procedures. RadNet also provides image-guided and interventional radiology services in selected markets, along with digital imaging, radiology, and information-technology solutions.

Founded in 1981, RadNet serves patients, physicians, hospitals, and other healthcare organizations through a network of outpatient imaging centers primarily located in the United States, including markets in California, New York, New Jersey, Maryland, and Delaware.

Read More

Earnings History for RadNet (NASDAQ:RDNT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in RadNet Right Now?

Before you consider RadNet, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and RadNet wasn't on the list.

While RadNet currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines